Currently, there are 111.36M common shares owned by the public and among those 106.20M shares have been available to trade.
Insiders at the company have transacted a total of 3 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 3 occasions, with total insider shares sold totaling 22,186 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 2.3300, up 14.85%. The company’s stock has a 5-day price change of 0.43% and -35.73% over the past three months. CHRS shares are trading -30.33% year to date (YTD), with the 12-month market performance down to -72.67% lower. It has a 12-month low price of $1.43 and touched a high of $8.65 over the same period. CHRS has an average intraday trading volume of 7.03 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.68%, -2.76%, and -41.41% respectively.
Institutional ownership of Coherus Biosciences Inc (NASDAQ: CHRS) shares accounts for 80.24% of the company’s 111.36M shares outstanding.
It has a market capitalization of $258.36M and a beta (3y monthly) value of 0.52. The earnings-per-share (ttm) stands at -$2.61. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.98% over the week and 9.55% over the month.
Earnings per share for the fiscal year are expected to increase by 48.44%, and 83.68% over the next financial year.
Looking at the support for the CHRS, a number of firms have released research notes about the stock. Robert W. Baird stated their Outperform rating for the stock in a research note on November 17, 2023, with the firm’s price target at $11.
